Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 10.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of 4D Molecular Therapeutics was 33.60% per year. The lowest was -126.70% per year. And the median was -4.40% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
4D Molecular Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
FDMT vs ACHV, CLYM, NVCT: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, 4D Molecular Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
4D Molecular Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 10.00% mean?
4D Molecular Therapeutics (FDMT) has a 3-Year EPS without NRI Growth Rate of 10.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for 4D Molecular Therapeutics and its competitors. According to the industry distribution chart, 4D Molecular Therapeutics ranks #668 out of 1160 companies in the Biotechnology industry, placing it in the top 57.6%.
Is 4D Molecular Therapeutics' 3-Year EPS without NRI Growth Rate too high?
4D Molecular Therapeutics' current 3-Year EPS without NRI Growth Rate is 10.00%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. 4D Molecular Therapeutics' value of 10.00% is 37.7% below this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #668 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' 3-Year EPS without NRI Growth Rate compare to ACHV and CLYM?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #668 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places 4D Molecular Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. 4D Molecular Therapeutics' value of 10.00% is 37.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current 3-Year EPS without NRI Growth Rate of 10.00% is 37.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for 4D Molecular Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current 3-Year EPS without NRI Growth Rate is 10.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $47.50, compared to a current price of $14.92 — trading 68.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 10.00% and 37.7% below the Biotechnology industry median of 16.05. 4D Molecular Therapeutics' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current 3-Year EPS without NRI Growth Rate is 10.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $14.92 is trading 68.6% below its estimated GF Value™ of $47.50.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
3-Year EPS without NRI Growth Rate: 10.00%
GF Value™: $47.50 vs. price of $14.92 (68.6% below fair value)
Industry Position: 37.7% below the Biotechnology median (#668 of 1160)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
54GF Score
Get the complete analysis for FDMT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
